Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.

Kong, Qingli; Wang, Hui; Ren, Xiaolei; Zhuo, Yue; Peng, Jing

Kong, Qingli; Wang, Hui; Ren, Xiaolei; Zhuo, Yue; Peng, Jing.

Afiliación

Kong Q; Phase I Clinical Trial Laboratory Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Wang H; Department of Pharmacy, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Ren X; Medical Big Data Center, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Zhuo Y; Department of Pharmacy, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Peng J; Department of Pharmacy, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.

Cancer Med ; 12(19): 19491-19499, 2023 10.

Article en En | MEDLINE | ID: mdl-37724594

Asunto(s)

Antineoplásicos Inmunológicos; Miastenia Gravis; Neoplasias; Humanos; Nivolumab/uso terapéutico; Ipilimumab/uso terapéutico; Inhibidores de Puntos de Control Inmunológico/uso terapéutico; Antineoplásicos Inmunológicos/uso terapéutico; Neoplasias/tratamiento farmacológico; Miastenia Gravis/inducido químicamente; Miastenia Gravis/epidemiología; Miastenia Gravis/complicaciones

Palabras clave

adverse drug reaction reporting systems; antineoplastic agents; computer-assisted signal processing; immunotherapy; myasthenia gravis; myasthenic syndrome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antineoplásicos Inmunológicos / Miastenia Gravis / Neoplasias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google